Statement of Changes in Beneficial Ownership (4)
November 14 2014 - 4:30PM
Edgar (US Regulatory)
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
KKR Biosimilar L.P.
|
2. Issuer Name
and
Ticker or Trading Symbol
Coherus BioSciences, Inc.
[
CHRS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O KOHLBERG KRAVIS ROBERTS & CO., L.P., 9 WEST 57TH STREET, SUITE 4200
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/12/2014
|
(Street)
NEW YORK, NY 10019
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
11/12/2014
|
|
C
|
|
2499499
|
A
|
(1)
|
2499499
|
I
|
See footnote
(2)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Series C Preferred Stock
|
(1)
|
11/12/2014
|
|
C
|
|
|
2499499
|
(1)
|
(3)
|
Common Stock
|
2499499
|
$0.00
|
0
|
I
|
See Footnote
(2)
|
Explanation of Responses:
|
(
1)
|
The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering.
|
(
2)
|
Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.
|
(
3)
|
Not applicable.
|
Remarks:
The Reporting Persons may have been deemed to have been ten percent owners of the Issuer's common stock as calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934 (the "Exchange Act") prior to the automatic conversion of all of the outstanding preferred stock of the Issuer immediately prior to the consummation of the initial public offering of the Issuer. This report shall not be deemed an admission that any such Reporting Person is subject to Section 16 of the Exchange Act. Each of the Reporting Persons (other than KKR Biosimilar L.P.) disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than KKR Biosimilar L.P.) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Report does not reflect shares of common stock of the Issuer purchased by KKR Biosimilar L.P. in the initial public offering following conversion of all of the outstanding preferred stock of the Issuer.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
KKR Biosimilar L.P.
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Biosimilar GP LLC
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Fund Holdings L.P.
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Fund Holdings GP Ltd
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Group Holdings L.P.
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Group Ltd
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR & Co. L.P.
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KKR Management LLC
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
KRAVIS HENRY R
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
ROBERTS GEORGE R
C/O KOHLBERG KRAVIS ROBERTS & CO.
L.P., 9 WEST 57TH STREET, SUITE 4200
NEW YORK, NY 10019
|
|
X
|
|
|
Signatures
|
KKR BIOSIMILAR L.P. By: KKR Biosimilar GP LLC, its general partner By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief Financial Officer
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR BIOSIMILAR GP LLC By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief Financial Officer
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR FUND HOLDINGS L.P. By: KKR Group Limited, the general partner of a general partner By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Director
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR FUND HOLDINGS GP LIMITED By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Director
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR GROUP HOLDINGS L.P. By: KKR Group Limited, its general partner By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Director
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR GROUP LIMITED By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Director
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR & CO. L.P. By: KKR Management LLC, its general partner By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief Financial Officer
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
KKR MANAGEMENT LLC By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief Financial Officer
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
HENRY R. KRAVIS By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
GEORGE R. ROBERTS By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact
|
|
11/14/2014
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024